Therachon
Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.
GLyPharma Therapeutic
Acquisition in 2018
GLyPharma Therapeutics, founded in Montréal in August 2012, focuses on developing innovative therapies for rare gastrointestinal diseases, including short bowel syndrome. The company has established a strategic partnership with Ferring Pharmaceuticals, a European firm specializing in peptide development, along with FONDS de solidarité FTQ and CTI Life Sciences Fund. GLyPharma's lead compound, FE 203799, is a long-acting Glucagon-Like Peptide-2 (GLP-2) receptor agonist that exhibits intestine-trophic and protective properties. This compound is being developed under an exclusive worldwide license from Ferring for its potential use in supportive care for oncology patients, specifically aimed at mitigating chemotherapy-induced intestinal mucositis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.